New research indicates that patients who stop using popular GLP-1 drugs like Mounjaro or Wegovy tend to recover lost weight far faster than those who end traditional lifestyle regimens.
Research printed in a prominent medical journal demonstrates that while overweight people frequently drop a large proportion of their body weight while undergoing treatment, the mass returns at an average rate of nearly a kilo each month once they quit.
"People purchasing such medications must be cognizant of the potential of fast rebound weight gain when the treatment ends," cautioned lead investigator Dr. Susan Jebb.
That rate of recovery means a reversion to pre-treatment mass in about a year and a half.
Comparing Approaches
The research, which reviewed 37 of studies involving over 9,000 of patients, contrasted the results of the injectable medications with other pills.
The team note that individuals who lose weight through dieting usually experience a slower weight regain—around 100 grams monthly—after stopping.
Explaining the Fast Rebound
Doctors propose the mode of action of the drugs explains the heightened weight return.
These medications mimic a natural hormone called glucagon-like peptide-1, which moderates feelings of fullness.
"Artificially providing the hormone levels far above than normal might result in the system to generate a reduced amount of its own natural GLP-1, and could diminish sensitivity to its effects," said Dr. Adam Collins, a nutrition expert.
"Stopping of this medication leads to appetite is no longer kept in check, making binge eating much more probable."
A Lifelong Condition?
Medical guidelines suggest the jabs for individuals with weight-linked health risks, accompanied by prescribed lifestyle changes.
Professionals say that, due to the high risk of weight regain, the therapy is often life-long.
This view is supported by pharmaceutical companies, who say that the results "highlight the persistent character of excess weight," comparing it to managing conditions like diabetes.
Patient Accounts
Users who have come off the jabs explain a sudden resurgence of cravings.
"It felt as if a trigger flipping and you become starving," described a patient.
This difficulty is exacerbated if patients have not developed lasting dietary or behavioural modifications during treatment.
Widespread Adoption
Survey data indicate that millions of adults in the UK have tried these injections in the last 12 months, with interest remaining high.
- Adoption is greater among women than men.
- The middle-aged demographic shows the highest level of interest.
- Many access the medications through private prescriptions rather than public health services.
Ultimately, clinicians stress that while the jabs are powerful tools for shedding pounds, they are not a permanent solution and maintained weight loss hinges on integrated behavioural changes.
